Domainex has expanded its assay services to include assay development and fragment-based screening using both biochemical and biophysical techniques. It has also launched a new collection of chemical fragments that is more diverse than other commercially available collections. This expansion allows Domainex to screen small molecules against various targets and identify hits using its in silico LeadBuilder technology.